Third Rock de­buts im­munome­tab­o­lism start­up Rheos with $60M launch round

Third Rock is push­ing one of its stealthy star­tups in­to the lime­light this morn­ing, with $60 mil­lion in fresh cap­i­tal and a plat­form tech that op­er­ates in the in­creas­ing­ly pop­u­lar field of im­munome­tab­o­lism.

The start­up, called Rheos Med­i­cines, has a drug dis­cov­ery tech that’s al­ready churned out two leads for the com­pa­ny that are both mov­ing in­to pre­clin­i­cal de­vel­op­ment.

Rheos, found­ed last sum­mer, is dig­ging in­to the new field of im­munome­tab­o­lism, which ba­si­cal­ly tries to un­der­stand — and lat­er har­ness — how a cell’s me­tab­o­lism af­fects dis­ease pro­gres­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.